ABC News’ World News Tonight – Dec. 5
“It can be done in the doctor’s office conceivably. There is great promise for the test but it’s not ready for prime time today,” said Dr. Theresa Boyle of Moffitt Cancer Center in Tampa, Fla.
The Daily Mail – Dec. 6
Speaking to DailyMail.com, Shelley S Tworoger, associate director of the Population Science division at Moffitt Cancer Center, said that we probably won't completely eliminate cancer as a disease.
Bloomberg – Dec. 6
“It’s clear the therapy can work,” said Fred Locke, a medical oncologist and leader of the immune cell therapy initiative at Moffitt Cancer Center in Tampa, Florida.
Targeted Oncology – Dec. 6
These study results and subsequent FDA approval are encouraging, Javier A. Pinilla-Ibarz, MD, PhD, a hematologist/oncologist in the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, Florida, explained, “It’s quite exciting to finally have a drug approved for such a rare entity.”
Business Observer – Dec. 6
Moffitt Cancer Center has hired Maria Muller as its executive vice president, chief philanthropy officer and foundation president.
Tampa Bay Business Journal – Dec. 7
For Mariana Bugallo-Muros, overseeing all human resources functions for more than 6,000 team members on Moffitt Cancer Centers four campuses is something she prides herself on doing successfully.
WTSP – Dec. 6
Tuesday evening outside Moffitt Cancer Center in Hillsborough County, Johanna and her son Michael Nicholas waited, they claim, for more than an hour for a cab to arrive.
WTSP – Dec. 5
For 12 years, Miles for Moffitt has brought thousands together in Tampa to fight cancer. It's drawn so much support, that in its 13th year, it has a new date and a new location.
But the mission to end cancer is the same. It's one that inspired a Tampa Police officer and made the brotherhood even stronger.
WTSP – Dec. 6
Think about the person you are gifting this donation to and what are they passionate about. If they love animals, donate to an animal rescue, maybe they lost a loved one to cancer and there's an organization like Moffitt Cancer Center that's near and dear to them.
MedPage Today – Dec. 5
Among eight DLBCL and transformed follicular lymphoma patients who ultimately went on to receive axicabtagene ciloleucel, six had stable local disease and one had a complete response (CR) in the targeted mass following RT, according to researchers led by Michael Jain, MD, PhD, of Moffitt Cancer Center in Tampa, Florida.
WTSP’s Great Day Live – Dec. 4
“This is Moffitt Cancer Center’s annual run/walk, which is Saturday morning in Downtown Tampa,” said Moffitt’s Allison Fonner.
Ocala Star Banner – Dec. 4
Dalton, 69, past president, CEO and center director with Moffitt Cancer Center in Tampa, gave the last Evening Lecture for 2018, “Moving From Reactive to Proactive Medicine Through Data Science,” at the Institute of Human and Machine Cognition to a standing-room-only audience Tuesday.
Bloomberg News – Dec. 3
“It can be a magic bullet, but that’s only for 39 or 40 percent of patients,” said Fred Locke, a medical oncologist and leader of the immune-cell therapy initiative at Moffitt Cancer Center in Tampa, Florida. “This is the best option we have right now, but it’s not a slam-dunk.” Also posted to the Los Angeles Times.
News Medical – Dec. 4
"This therapy has been a game-changer for patients with large B cell lymphoma who have failed two or more lines of therapy. Our ZUMA-1 clinical trial data show durable response beyond 2 years for nearly 40 percent of patients who had almost no chance for complete responses with conventional chemotherapy," said Frederick Locke, M.D., lead author of the article and associate member and vice chair of the Blood and Marrow Transplant and Cellular Immunotherapy Department, and co-leader of the Immunology Program at Moffitt Cancer Center.
News Medical – Dec. 3
Moffitt Cancer Center partnered with 16 academic cancer centers to analyze real world data of 274 patients treated commercially with Yescarta® (axicabtagene ciloleucel), one of two CAR T products that is now standard of care for patients with diffuse large B cell lymphoma (DLBCL) who have not responded to two or more therapies.
OBROncology.com – Dec. 3
The model was developed using clinical and mutational data from patients with MDS in a combined cohort from the Cleveland Clinic and Munich Leukemia Laboratory (training cohort, n=1471) and validated in a separate cohort (validation cohort, n=831) from the Moffitt Cancer Center.
Medscape – Dec. 3
The model was developed through use in a combined cohort of patients from the Cleveland Clinic and the Munich Leukemia Laboratory (n = 1471) and was then validated in a separate cohort from the Moffitt Cancer Center (n = 831).
Hematology Times – Dec. 3
Treatment with luspatercept was “very well tolerated,” and responses were durable, with approximately 40% of patients remaining transfusion-free after 1 year of therapy, said senior investigator Alan F. List, MD, of Moffitt Cancer Center in Tampa, Florida, during a press conference at the meeting.
OncLive – Dec. 2
Luspatercept is a first-in-class erythroid maturation agent that is believed to regulate late-stage RBC maturation. Lower-risk MDS-associated anemia may be associated with ineffective erythropoiesis, which leads to anemia, and further, RBC transfusion dependence, explained List, who is president and chief executive officer of Moffitt Cancer Center in Tampa, Florida.
Obroncology.com – Dec. 2
Alan F. List, MD, Moffitt Cancer Center, Tampa, Florida, said that the rationale for the MEDALIST trial (NCT02631070) was based on the lack of treatment options for patients with low risk MDS. There has not been a new treatment for this condition in 12 years.
WTSP – Dec. 2
“When I’m putting these things together, I’m not really thinking about what I’m doing, I just do it,” says Rottum, who also works part-time at Moffitt Cancer Center.
Onco’Zine – Dec. 2
They trained the system using patient data from Cleveland Clinic and Munich Leukemia Laboratory (1,471 patients total) and validated it in a separate collection of patient data from Moffitt Cancer Center (831 patients).
Evaluate – Dec. 1
Dr Alan List, of the Moffitt Cancer Center in Florida, predicted success for Commands, saying he expects luspatercept to be more effective than ESAs.
Healio – Dec. 1
“Patients with lower-risk, red blood cell transfusion-dependent myelodysplastic syndrome have a worse prognosis owing to greater risk for progression to acute myeloid leukemia and inferior OS compared with transfusion-independent patients,” Alan F. List, MD, president and CEO of Moffitt Cancer Center, told HemOnc Today.
Tampa Bay Business Journal – Nov. 30
Moffitt utilizes a multimodal data-driven approach to ensure dignity, belonging and equity among team members, said Mariana Bugallo-Muros in submission materials.
Self Magazine – Nov. 30
Either way, you should only get testing after receiving thorough information about the process and what the results might mean, Susan Vadaparampil, Ph.D., M.P.H., a senior researcher in the Health Outcomes and Behavior Department at Moffitt Cancer Center, tells SELF.
OncLive – Nov. 30
Ryan Bookout, PharmD, president, Hematology/Oncology Pharmacy Association, clinical pharmacist, Moffitt Cancer Center, discusses the questionable sustainability of the field of oncology as drug prices continue to rise.
Endpoint News – Nov. 30
The lead investigator for the MDS study is David Sallman from the Moffitt Cancer Center.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.